Supplementary Table 2.
Univariate analyses of factors associated with overall survival of HCC in samples combined discovery and replication sets (n=1125).
| Variable | P-value | HR | 95% CI | |
|---|---|---|---|---|
| Lower | Upper | |||
| Gender (Male vs. Female) | 0.483 | 1.088 | 0.860 | 1.376 |
| Age, years (>55 vs. ≤55) | 0.579 | 0.954 | 0.808 | 1.126 |
| AFP, ng/ml (>20 vs. ≤20) | 5.36×10−8 | 1.636 | 1.370 | 1.954 |
| ALT, ng/ml (>75 vs. ≤75) | 0.177 | 1.164 | 0.934 | 1.451 |
| Tumor size, cm (>5 vs. ≤5) | 5.64×10−23 | 2.333 | 1.972 | 2.760 |
| Tumor number (multiple vs. single) | 0.021 | 1.290 | 1.040 | 1.600 |
| Vascular invasion (yes vs. no) | 8.96×10−30 | 2.594 | 2.200 | 3.059 |
| PVTT (yes vs. no) | 1.33×10−40 | 4.322 | 3.486 | 5.359 |
| Extrahepatic metastasis (yes vs. no) | 3.33×10−6 | 2.305 | 1.621 | 3.278 |
| TNM stage (III–IV vs. I–II) | 2.52×10−34 | 2.973 | 2.496 | 3.541 |
| BCLC stage (B–C vs. 0–A) | 2.42×10−21 | 2.569 | 2.114 | 3.122 |
| Child-Pugh stage (B vs. A) | 1.91×10−6 | 2.299 | 1.632 | 3.240 |
| Tumor differentiation (III–IV vs. I–II) | 1.19×10−6 | 1.532 | 1.290 | 1.820 |
| Liver cirrhosis (yes vs. no) | 0.099 | 0.843 | 0.688 | 1.033 |
| Tumor encapsulation (none vs. complete) | 1.70×10−7 | 1.574 | 1.328 | 1.866 |
| HBsAg (negative vs. positive) | 0.544 | 1.073 | 0.855 | 1.347 |
| HBcAb (negative vs. positive) | 0.540 | 0.909 | 0.670 | 1.233 |
| Anti-HCV (negative vs. positive) | 0.354 | 1.423 | 0.675 | 3.000 |
HCC – hepatocellular carcinoma; AFP – alpha fetoprotein; ALT – alanine aminotransferase; BCLC – Barcelona Clinic Liver Cancer; CI – confidence interval; HBsAg – hepatitis B surface antigen; HBcAb – hepatitis B core antibody; HCV – hepatitis C virus; HR – hazard ratio; PVTT – portal vein tumor thrombus; TNM – tumor node metastasis.